Management of the patent ductus arteriosus in preterm infants.

Cyclo-oxygenase inhibitors (COX-I) Hemodynamically significant (hs)-PDA Patent ductus arteriosus Preterm infants Procedural PDA closure

Journal

Paediatrics & child health
ISSN: 1205-7088
Titre abrégé: Paediatr Child Health
Pays: England
ID NLM: 9815960

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 26 11 2020
accepted: 07 07 2021
entrez: 11 3 2022
pubmed: 12 3 2022
medline: 12 3 2022
Statut: epublish

Résumé

Management of the patent ductus arteriosus (PDA) is one of the most contentious topics in the care of preterm infants. PDA management can be broadly divided into prophylactic and symptomatic therapy. Prophylaxis with intravenous indomethacin in extremely low birth weight infants may reduce severe intraventricular hemorrhage. Echocardiography should be routinely used to confirm the presence of a PDA before considering symptomatic therapy. A symptomatic PDA can be managed conservatively, using pharmacotherapy or with procedural closure. Ibuprofen should be considered as the pharmacotherapy of choice for a symptomatic PDA. High-dose ibuprofen may be preferable, especially for preterm infants beyond the first 3 to 5 days of age. If pharmacotherapy fails (after two courses) or is contraindicated, procedural closure may be considered for infants with a persistent PDA with significant clinical symptoms in addition to echocardiographic signs of a large PDA shunt volume and pulmonary over-circulation.

Identifiants

pubmed: 35273674
doi: 10.1093/pch/pxab085
pii: pxab085
pmc: PMC8900701
doi:

Types de publication

Journal Article Review

Langues

eng eng

Pagination

63-64

Informations de copyright

© Canadian Paediatric Society 2022. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Souvik Mitra (S)

Canadian Paediatric Society, Fetus and Newborn Committee, Drug Therapy and Hazardous Substances Committee, Ottawa, Ontario, Canada.

Dany Weisz (D)

Canadian Paediatric Society, Fetus and Newborn Committee, Drug Therapy and Hazardous Substances Committee, Ottawa, Ontario, Canada.

Amish Jain (A)

Canadian Paediatric Society, Fetus and Newborn Committee, Drug Therapy and Hazardous Substances Committee, Ottawa, Ontario, Canada.

Geert 't Jong (G')

Canadian Paediatric Society, Fetus and Newborn Committee, Drug Therapy and Hazardous Substances Committee, Ottawa, Ontario, Canada.

Classifications MeSH